首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Discovery of N-(2-phenyl-1H-benzo[d]imidazol-5-yl)quinolin-4-amine derivatives as novel VEGFR-2 kinase inhibitors
【24h】

Discovery of N-(2-phenyl-1H-benzo[d]imidazol-5-yl)quinolin-4-amine derivatives as novel VEGFR-2 kinase inhibitors

机译:将N-(2-苯基-1H-苯并[D] Imidazol-5-Y1)喹啉-4-胺衍生物的发现为新型VEGFR-2激酶抑制剂

获取原文
获取原文并翻译 | 示例
           

摘要

Inhibition of the VEGF signaling pathway has become a valuable approach in the treatment of cancers. In this work, a series of N-(2-phenyl-1H-benzo[d]imidazol-5-yl)quinolin-4-amine derivatives were designed and identified as potent inhibitors of VEGFR-2 (KDR) kinase. These compounds with quinoline scaffold and benzimidazole moiety were synthesized and their biological activities against VEGFR-2 and two human cancer cell lines were evaluated. Among them, compound 7s exhibited the most potent inhibitory activity against VEGFR-2 with IC50 of 0.03 mu M and it also showed the highest anticancer activity against the tested cancer cell lines with IC50 of 1.2 mu M against MCF-7 and 133 mu M against Hep-G2. Docking simulation supported the initial pharmacophoric hypothesis and suggested a common mode of interaction at the ATP-binding site of VEGFR-2, which demonstrates that compound 7s is a potential agent for cancer therapy deserving further researching. (C) 2014 Elsevier Masson SAS. All rights reserved.
机译:VEGF信号传导途径的抑制已成为治疗癌症的宝贵方法。在这项工作中,一系列的N-(2-苯基-1H-苯并[d]咪唑-5-基)喹啉-4-胺衍生物被设计和鉴定为VEGFR-2(KDR)激酶的有效抑制剂。合成这些具有喹啉支架和苯并咪唑部分的化合物,并评估对VEGFR-2和两种人类癌细胞系的生物活性。其中,化合物7S对VEGFR-2具有IC50的最有效的抑制活性,IC50为0.03μm,它还向测试的癌细胞系中的抗癌活性与IC50的IC50对抗MCF-7和133亩HEP-G2。对接模拟支持的初始药效假说和VEGFR-2的ATP结合位点,这表明化合物7S是用于癌症治疗值得进一步研究的电位剂建议相互作用的共模。 (c)2014年Elsevier Masson SAS。版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号